Among the drugs in the Antibody Drug Conjugates (ADC), Adcetris will witness faster growth than Kadcyla
Date: 25 March 2017
Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.
Globally, only two ADCs are present in the market – Adcetris and Kadcyla. Adcetris was approved by FDA in 2011 and Kadcyla in 2013. Mylotarg, a drug developed by Pfizer, was the first ADC ever approved but was voluntarily withdrawn from the market in 2010 but is still available in Japan. Approval and successful commercialization of Adcetris and Kadcyla have made the biopharmaceutical market realise the immense potential that ADC holds. There has been heavy investment in the development of ADCs by leading biotechnology and biopharmaceutical companies with about 50 molecules presently in the clinical development stage and more than 190 trials taking place around the world. Several molecules are currently in late stage of clinical trials and are expected to gain approval and enter market in next few years which will result in heavy growth of global ADC market. Companies have been strategically expanding their market through multiple licensing of proprietary ADC technology, and collaboration amongst companies for developing ADCs. Major trend that the ADC market has been witnessing over the years is outsourcing of ADC production to CMOs (Contract Manufacturing Organisation)
Among the drugs, Adcetris will witness faster growth than Kadcyla as the former is expecting approval for more indications in the forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).